AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Bellicum Pharmaceuticals Inc (OTC:BLCM)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | -- |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 1.500/0.100 |
| EBITDA (in USD) | -23.817M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -0.72 |
| Total Assets (in USD) | 23.823M |
|---|---|
| Total Liabilities (in USD) | 21.808M |
| Revenue TTM (in USD) | 1.508M |
| Cash (in USD) | 21.837M |
| Market Cap (in USD) | 1.943 M |
| Revenue Per Share TTM | 0.049 |
| Gross Profit TTM (in USD) | -17.378M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Employees: 13
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Richard A. Fair | Pres, CEO & Director | 1969 |
| 2. | Ms. Charity D. Scripture M.S., Pharm.D. | Chief Devel. Officer | 1975 |
| 3. | Mr. Charles S. Grass | Principal Accounting Officer | 1960 |
| 4. | Mr. Joseph Senesac | Sr. VP of Technical Operations & Quality | 1970 |
| 5. | Dr. Alan K. Smith Ph.D. | Chief Scientific Officer | 1958 |
| 6. | Dr. Aaron E. Foster | Head of Research & Sr. VP | 1973 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.560 0.691% | 81.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.410 0.506% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.290 0.280% | 455.39 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.820 0.540% | 518.25 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -24.971M | -9.705M | -7.722M | -112.477M | -98.036M |
| Minority Interest | - | - | - | - | - |
| Net Income | -24.973M | -9.578M | -8.619M | -126.092M | -98.036M |
| Selling General Administrative | 5.717M | 7.01M | 15.531M | 29.972M | 25.434M |
| Gross Profit | 1.5M | 6.2M | 0.5M | 7.143M | 1.12M |
| Reconciled Depreciation | 0.011M | 0.138M | 1.874M | 8.506M | 6.698M |
| Ebit | -26.981M | -24.866M | -51.692M | -87.364M | -102.164M |
| Ebitda | -28.934M | -24.349M | -53.584M | -68.172M | -95.466M |
| Depreciation And Amortization | -1.953M | 0.517M | -1.892M | 19.192M | 6.698M |
| Operating Income | -26.981M | -24.866M | -51.692M | -87.364M | -95.466M |
| Other Operating Expenses | 28.481M | 30.588M | 54.583M | 94.507M | 96.586M |
| Interest Expense | 0M | 0.004M | 2.659M | 4.28M | 4.199M |
| Tax Provision | 0.002M | - | - | - | - |
| Interest Income | - | 0.032M | 0.387M | 1.351M | 1.639M |
| Net Interest Income | 0.046M | 0.028M | -2.272M | -2.929M | -2.56M |
| Income Tax Expense | 0.002M | -0.127M | 0.897M | 13.615M | 1.629M |
| Total Revenue | 1.5M | 6.2M | 0.5M | 7.143M | 1.12M |
| Total Operating Expenses | 28.481M | 30.588M | 54.583M | 94.507M | 96.586M |
| Cost Of Revenue | - | - | - | 62.471M | 0.436M |
| Total Other Income Expense Net | 2.01M | 15.161M | 43.97M | -25.113M | -0.01M |
| Net Income From Continuing Ops | -24.973M | -9.705M | -7.722M | -112.477M | -98.036M |
| Net Income Applicable To Common Shares | - | -9.705M | -7.722M | -112.477M | -98.036M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 23.823M | 49.143M | 40.584M | 116.25M | 121.501M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.964M | 1.269M | 0.802M | 0.884M | 1.387M |
| Total Liab | 21.808M | 24.748M | 43.081M | 142.467M | 53.023M |
| Total Stockholder Equity | 2.015M | 24.395M | -2.497M | -26.217M | 68.478M |
| Other Current Liab | 3.286M | 6.622M | 18.82M | 70.551M | 9.007M |
| Common Stock | 0.087M | 0.085M | 0.084M | 0.507M | 0.442M |
| Capital Stock | 0.087M | 0.085M | 0.084M | 0.507M | 0.442M |
| Retained Earnings | -575.425M | -550.452M | -540.747M | -533.025M | -420.548M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0.952M | 0.825M | 5.328M |
| Cash | 21.837M | 46.156M | 35.495M | 91.028M | 43.695M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 3.772M | 6.712M | 24.701M | 94.418M | 15.804M |
| Current Deferred Revenue | - | - | 4.165M | 9.77M | 2.983M |
| Net Debt | -21.837M | -46.156M | -34.326M | -52.993M | -7.732M |
| Short Term Debt | - | - | 0.825M | 11.454M | 0.04M |
| Short Long Term Debt | - | - | - | 11M | - |
| Short Long Term Debt Total | - | - | 1.169M | 38.035M | 35.963M |
| Other Stockholder Equity | 559.671M | 557.064M | 520.469M | 485.16M | 488.728M |
| Property Plant Equipment | - | 0.012M | 0.834M | 2.529M | 20.878M |
| Total Current Assets | 23.801M | 49.131M | 39.443M | 111.854M | 95.295M |
| Long Term Investments | - | - | - | - | 0M |
| Short Term Investments | - | - | - | 0M | 49.304M |
| Net Receivables | 0.205M | 0.205M | 0.002M | 0.303M | 2.296M |
| Long Term Debt | - | - | - | 25.717M | 35.832M |
| Inventory | -0.205M | 1.501M | 3.144M | 19.639M | -1.387M |
| Accounts Payable | 0.486M | 0.09M | 0.891M | 2.643M | 3.774M |
| Accumulated Other Comprehensive Income | -0.354M | -0.338M | -0.339M | -0.327M | -0.144M |
| Non Currrent Assets Other | - | - | 0.307M | 0.825M | 5.328M |
| Non Current Assets Total | 0.022M | 0.012M | 1.141M | 4.396M | 26.206M |
| Capital Lease Obligations | - | 0M | 1.169M | 1.318M | 0.091M |
| Long Term Debt Total | - | - | - | 25.717M | 35.923M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.021M | 0.893M | 14.08M | 49.379M | 71.362M |
| Total Cashflows From Investing Activities | - | 0.893M | 14.08M | 48.857M | 10.41M |
| Total Cash From Financing Activities | 0M | 32.873M | -14.238M | 74.088M | 68.109M |
| Net Income | -24.973M | -9.705M | -7.722M | -112.477M | -98.036M |
| Change In Cash | -25.82M | 10.661M | -56.82M | 45.148M | 3.639M |
| Begin Period Cash Flow | 47.657M | 36.996M | 93.816M | 48.668M | 45.029M |
| End Period Cash Flow | 21.837M | 47.657M | 36.996M | 93.816M | 48.668M |
| Total Cash From Operating Activities | -25.783M | -23.106M | -56.65M | -77.569M | -74.782M |
| Depreciation | 0.011M | 0.138M | 1.874M | 8.506M | 6.698M |
| Other Cashflows From Investing Activities | - | - | 14.705M | 49.379M | -59.335M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | -0.301M | -0.606M | 3.244M |
| Sale Purchase Of Stock | - | - | 0.09M | 51.263M | 68.14M |
| Other Cashflows From Financing Activities | -0.021M | 32.908M | 0.09M | 65.158M | 3.28M |
| Capital Expenditures | 0.021M | 0.007M | 0.625M | 0.522M | 1.617M |
| Change In Working Capital | -1.466M | -2.353M | -8.164M | -6.904M | 2.018M |
| Other Non Cash Items | -1.964M | 0.023M | 0.964M | 1.689M | 0.61M |
| Free Cash Flow | -25.804M | -23.113M | -57.275M | -78.091M | -76.399M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Extended Market Index Investor | 2 years ago | 95994 |
| 2. | Fidelity® Extended Market Index | 2 years ago | 36616 |
| 3. | Fidelity® NASDAQ Composite Index® | 2 years ago | 22867 |
| 4. | BlackRock Extended Mkt Composite | 2 years ago | 8791 |
| 5. | Vanguard U.S. Eq Idx £ Acc | 2 years ago | 6948 |
| 6. | Northern Trust Extended Eq Market Idx | 2 years ago | 6005 |
| 7. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 6005 |
| 8. | Fidelity® Series Total Market Index | 2 years ago | 5837 |
| 9. | Fidelity® Total Market Index | 2 years ago | 5352 |
| 10. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 3705 |
| 11. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 3136 |
| 12. | State St US Extended Mkt Indx NL Cl C | 2 years ago | 1810 |
| 13. | SSgA U.S. Extended Market Index Class I | 2 years ago | 1810 |
| 14. | Spartan Extended Market Index Pool E | 2 years ago | 1531 |
| 15. | NT US Market Cap Idx Fd - L | 2 years ago | 658 |
| 16. | Northern Trust Wilshire 5000 | 2 years ago | 658 |
| 17. | SSgA U.S. Total Market Index Strategy | 2 years ago | 569 |
| 18. | Spartan Total Market Index Pool E | 2 years ago | 567 |
| 19. | State St US Ttl Mkt Indx NL Cl C | 2 years ago | 40 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Ikarian Capital, LLC | 2 years ago | 448101 |
| 2. | Long Focus Capital Management, LLC | 2 years ago | 327692 |
| 3. | Baker Bros Advisors LP | 2 years ago | 249123 |
| 4. | BlackRock Inc | 2 years ago | 75753 |
| 5. | Geode Capital Management, LLC | 2 years ago | 72770 |
| 6. | Vanguard Group Inc | 2 years ago | 66309 |
| 7. | BOOTHBAY FUND MANAGEMENT, LLC | 2 years ago | 45057 |
| 8. | Susquehanna International Group, LLP | 2 years ago | 30177 |
| 9. | State Street Corporation | 2 years ago | 27245 |
| 10. | JANE STREET GROUP, LLC | 2 years ago | 20077 |
| 11. | Renaissance Technologies Corp | 2 years ago | 14000 |
| 12. | Morgan Stanley - Brokerage Accounts | 2 years ago | 13962 |
| 13. | Northern Trust Corp | 2 years ago | 10981 |
| 14. | Tower Research Capital LLC | 2 years ago | 7844 |
| 15. | Tekla Capital Management LLC | 2 years ago | 6000 |
| 16. | UBS Group AG | 2 years ago | 3057 |
| 17. | Advisor Group Holdings, Inc. | 2 years ago | 2998 |
| 18. | Group One Trading, LP | 2 years ago | 1066 |
| 19. | Wells Fargo & Co | 2 years ago | 782 |
| 20. | Princeton Global Asset Management LLC | 2 years ago | 100 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...